CD BioSciences is a world-leading biotechnology company with advanced equipment and experienced staff. Our high-throughput peptidomimetic development platform can provide comprehensive, professional development of target-based highly-stable peptidomimetic according to customers specific requirements.
Introduction to Target-Based Peptidomimetic Development
An in-depth understanding of the function and pathology of cells provides many potential targets for the development of new therapeutic and diagnostic agents. However, a general problem with translating this knowledge into therapeutics is that these targets are functionally incapable of drug development. Screening methods similar to mRNA display and phage display have been shown to generate peptidomimetics capable of binding to and modulating PPI for the study of a wide range of protein interactions. Undoubtedly, the identification and better understanding of the interaction between peptidomimetics and their therapeutic targets has dramatically changed the paradigm of drug discovery.
As an advanced peptidomimetic development platform, PepDomTM is committed to in-depth research in the range of therapeutic targets. Using our advanced high-throughput screening platform, we can quickly analyze the interaction between the target and the ligand, so as to find the target peptidomimetic. In addition, targeted peptidomimetics developed using the unique technology of PepDomTM have higher stability and bioavailability than traditional peptides.
Our Services
The target-based peptidomimetic development services we provide include but are not limited to the following aspects:
In biology, there are hundreds of different signaling molecules that transmit information between cells. Signal molecules themselves are not directly used for information, and their function is to transmit information by binding to receptors. Targeting signal molecules to block the transmission of cellular information is one of the current strategies for drug development. CD BioSciences provides comprehensive peptidomimetic development services for signaling molecules.
Receptors are components of cell membranes or cells that can recognize and bind biologically active molecules, which recognize, receive and transmit signals to produce biological effects. More than 50% of the drugs currently on the market are studied with receptors as targets. CD BioSciences provides comprehensive peptidomimetics development for receptors.
Transcription factors play an important role in the regulation of all cellular genomes by binding to specific DNA sites and controlling the spatial transcriptional output of genes. The great potential of targeting TFs is best demonstrated in anticancer therapy, and they are more specific for disease regulation than upstream signaling proteins such as GPCRs or kinases. CD BioSciences offers comprehensive peptidomimetics development for transcription factors.
RNA is an important bridge connecting DNA and protein. If RNA or DNA is used as a target, it can not only greatly expand the proportion of targets in the human genome for treating diseases, but also will not be restricted by its own spatial structure. Therefore, nucleic acid-targeting drugs are expected to overcome the limitations of existing targets and have great potential to treat "untargetable" and "undruggable" diseases. CD BioSciences provides comprehensive peptidomimetics development for nucleic acids.
Enzymes are proteins synthesized by living cells that can effectively catalyze specific substrates and are important catalysts for biochemical reactions in the body. Because enzymes are involved in the pathogenesis of certain diseases and produce some pathological reaction mediators or regulators under the catalysis of enzymes, enzymes have become an important class of drug targets. CD BioSciences offers comprehensive peptidomimetics development for enzymes.
Our Service Processes
The target areas that CD BioSciences focuses on are not limited to those mentioned above. As long as you are interested, you can contact us to obtain our professional development plans and opinions.
References
- Lenci, E., & Trabocchi, A. (2020). Peptidomimetic toolbox for drug discovery. Chemical Society Reviews, 49(11): 3262-3277.
- Sawyer, T. K. (2006). Peptidomimetic and nonpeptide drug discovery: receptor, protease, and signal transduction therapeutic targets. Comprehensive Medicinal Chemistry II.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
